Arsia, Biogen in deal for subcutaneous biologics

Biogen Inc. (NASDAQ:BIIB) partnered with Arsia Therapeutics Inc. (Cambridge, Mass.) to develop subcutaneous formulations of intravenous hemophilia therapies.

Arsia CEO Amy Schulman said details about the therapies covered under the deal are not disclosed, including whether they are marketed or in development. Biogen markets hemophilia therapies Eloctate and Alprolix, which are both long-acting factor replacement therapies that are administered via intravenous injection. ...